Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Aprea Therapeutics, Inc. (NASDAQ: APRE)
APRE Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
84.90%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
167.10%
APRE Stock Analysis
APRE
PE Ratio:
APRE
PEG Ratio:
Not Available
APRE
Forward EPS Growth (12 month):
0.00%
APRE
PS Ratio:
37.8
APRE
PSG Ratio:
0.3
APRE
Forward Revenue Growth (12 month):
111.50%
APRE Articles
No data was found